Aerie Pharmaceuticals Logo

Investors

We began with a vision, and now we’ve grown into an ophthalmic pharmaceutical company focused on discovering, developing and commercializing first-in-class therapies for treating open-angle glaucoma and other diseases of the eye.

Leadership Team at Aerie Pharmaceuticals

LEADERSHIP TEAM

Meet the eye care VISIONaerieS™ building the next major ophthalmic pharmaceutical company.

MORE
Nasdaq tower on listing day of Aerie Pharmaceuticals

STOCK INFORMATION

NASDAQ: AERI
$65.75
Aug 14, 2018 4:00 PM EDT

MORE
Aerie Pharmaceuticals' 2017 Annual Report

REPORTS AND FILINGS

Review the latest annual report, quarterly reports, and other SEC filings.

MORE
TOP